Drug combination before surgery for PD-L1-positive lung cancer
Part of Lungs & breathing clinical trials.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) given before surgery for people with a specific type of lung cancer that is PD-L1 positive and can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have non-small cell lung cancer (the most common type) that can be removed by surgery.
- Your cancer is at stage II, IIIA, or IIIB (meaning it has not spread far).
- Your tumor tests positive for a protein called PD-L1 (at least 1%).
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your tumor does not have certain gene changes (EGFR or ALK) that are often targeted by other drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
Hear when a new Resectable Stage II-IIIB NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.